1.
|
Phase: Phase III, Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 3 to 21 Sponsor: NCI Protocol IDs: NCI-2011-02616, ACNS0822, CDR0000688443, U10CA098543, COG-ACNS0822, NCT01236560
|
|
2.
|
Phase: Phase II, Phase I Type: Treatment Status: Active Age: 2 to 32 Sponsor: Pharmaceutical / Industry Protocol IDs: CNS 0201, NCT00179907
|
|
3.
|
Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 1 to 21 Sponsor: NCI, Other Protocol IDs: CDR0000647587, COG-ADVL0912, ADVL0912, NCT00939770
|
|
4.
|
Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 12 to 17 Sponsor: Pharmaceutical / Industry Protocol IDs: CLDE225X2104, 2010-019348-37, NCT01125800
|
|
5.
|
Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 3 to 21 Sponsor: NCI Protocol IDs: NCI-2011-02600, ACNS0927, U10CA098543, U10CA97452, COG-ACNS0927, NCT01189266
|
|
6.
|
Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 2 to 20 Sponsor: NCI, Pharmaceutical / Industry Protocol IDs: 100220, IND 59,056, NCT01222780
|
|
7.
|
Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 4 to 21 Sponsor: Other Protocol IDs: 10-096, NCT01294670
|
|
8.
|
Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 21 and under Sponsor: NCI Protocol IDs: PBTC-033, PBTC-033, NCT01514201
|
|
9.
|
Phase: Phase II, Phase I Type: Treatment Status: Active Age: 12 and over Sponsor: Other Protocol IDs: 2010-0700, NCT01590069
|
|
10.
|
Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: Any age Sponsor: Other Protocol IDs: 05-122, MSKCC-05122, NCT00445965
|
|
11.
|
Phase: Phase II Type: Treatment Status: Active Age: 3 to 21 Sponsor: Other Protocol IDs: 24549, NCT00879437
|
|
12.
|
Phase: Phase II Type: Treatment Status: Active Age: 6 months to 17 years Sponsor: Other Protocol IDs: CDR0000066490, BC-BT-10, NCT00003458
|
|
13.
|
Phase: Phase II Type: Treatment Status: Active Age: 6 months to 17 years Sponsor: Other Protocol IDs: CDR0000066504, BC-BT-13, NCT00003468
|
|
14.
|
Phase: Phase II Type: Treatment Status: Active Age: 6 months to 17 years Sponsor: Other Protocol IDs: CDR0000066513, BC-BT-22, NCT00003476
|
|
15.
|
Phase: Phase II Type: Treatment Status: Active Age: 6 months to 17 years Sponsor: Other Protocol IDs: CDR0000066514, BC-BT-23, NCT00003477
|
|
16.
|
Phase: Phase II Type: Treatment Status: Active Age: 1 to 21 Sponsor: NCI, Other Protocol IDs: DOD W81XWH-05-1-0615, UAB, NCT01158651
|
|
17.
|
Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 0 to 21 Sponsor: Other Protocol IDs: Poly ICLC, NCT01188096
|
|
18.
|
Phase: Phase II Type: Natural history/Epidemiology, Treatment Status: Active Age: 1 to 25 Sponsor: NCI, Other Protocol IDs: 10-206, NCT01288235
|
|
19.
|
Phase: Phase II Type: Treatment Status: Active Age: Under 18 Sponsor: Other Protocol IDs: CNMC-VRL, NCT01497860
|
|
20.
|
Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: Under 22 Sponsor: NCI Protocol IDs: NCI-2012-00703, ACNS1022, U10CA098543, CDR0000728296, COG-ACNS1022, NCT01553149
|
|
21.
|
Phase: Phase II Type: Treatment Status: Active Age: 12 to 21 Sponsor: NCI, Other Protocol IDs: PBTC-036, NCI-2013-00482, U01CA081457, NCT01836549
|
|
22.
|
Phase: Phase I Type: Treatment Status: Active Age: 3 to 70 Sponsor: Other Protocol IDs: MCW-7594, MCW-CHW-511, MCW-CHW-9411, NCI-V95-0652, NCT00002647
|
|
23.
|
Phase: Phase I Type: Treatment Status: Active Age: Any age Sponsor: NCI, Other Protocol IDs: 03-133, P30CA008748, MSKCC-03133, NCT00089245
|
|
24.
|
Phase: Phase I Type: Treatment Status: Active Age: 1 and over Sponsor: NCI Protocol IDs: CPMC-AAAA-4229, CPMC-14220, NCT00324844
|
|
25.
|
Phase: Phase I Type: Treatment Status: Active Age: 21 and under Sponsor: Other Protocol IDs: RADBEV, NCT00756340
|